UK Medicines, Medical Devices & Healthcare Regulations, MHRA Rules & Statutory Instruments
Track MHRA marketing authorisations, International Recognition Procedure (IRP), UKCA medical device transition rules, Windsor Framework medicine regulations, and vigilance statutory instruments.
Medicines, Medical Devices & Healthcare Products Regulatory Landscape & Compliance Overview
Official IntelligencePolicyIndex indexes real-time gazette notifications, policy orders, tariff determinations, and compliance circulars issued across the Medicines, Medical Devices & Healthcare Products sector. Regulatory intelligence is aggregated across central ministries, state regulatory commissions, and statutory authorities.
Statutory Directives
Official Extraordinary Gazettes, S.O. & G.S.R. orders, and executive notifications.
Compliance Mandates
Sector-specific regulatory obligations, licensing norms, and statutory filing guidelines.
Other Verticals in Healthcare, Pharmaceuticals & Life Sciences
Looking for Weekly Policy & Regulatory Briefings?
Access curated sector roundups, executive summaries, and downloadable PDF intelligence reports.
Official Medicines, Medical Devices & Healthcare Products Gazettes & Notifications
Frequently Asked Questions on Medicines, Medical Devices & Healthcare Products Regulations
How does UK medicines licensing work post-Brexit?
The MHRA operates standalone licensing routes including the International Recognition Procedure (IRP) and the Innovative Licensing and Access Pathway (ILAP), independent of the EMA, using powers under the Human Medicines Regulations 2012 as amended by post-Brexit SIs.
What is the MHRA International Recognition Procedure (IRP)?
Introduced in January 2024 to replace the EC Decision Reliance Procedure, the IRP allows the MHRA to accelerate UK marketing authorisation evaluations by leveraging approvals from designated Reference Regulators including the US FDA, EMA, Health Canada, Swissmedic, PMDA (Japan), TGA (Australia), and HSA (Singapore).
How does the Windsor Framework affect medicine supply to Northern Ireland?
Under the Windsor Framework human medicines agreement effective January 2025, all human medicines placed on the market in Northern Ireland are regulated exclusively by the MHRA under UK rules, eliminating the previous dual-regulatory requirement and allowing medicines to feature a single 'UK Only' pack label valid across Great Britain and Northern Ireland.
What is the UKCA marking for medical devices?
The UK Conformity Assessed (UKCA) mark is required for medical devices placed on the Great Britain market. Devices must be registered with the MHRA and, for higher-risk classes, assessed by a UK Approved Body under the UK Medical Devices Regulations 2002 as amended.
What is the transition timetable for UKCA marking of medical devices?
Under the Medical Devices (Amendment) Regulations 2023, valid CE-marked general medical devices under EU directives can remain on the GB market until 30 June 2028 (or 2030 under EU MDR), while the MHRA develops a modernized pre-market regulatory framework establishing stricter post-market surveillance and designated UK Approved Bodies.
What are the UK Post-Market Surveillance (PMS) statutory requirements for medical devices?
The UK PMS Statutory Instrument mandates medical device manufacturers to implement proactive PMS plans, produce Periodic Safety Update Reports (PSURs) based on device classification, report serious incidents within shortened statutory timelines, and maintain continuous clinical evaluation throughout the device lifecycle.